These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 26918279)
21. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Yamashita F; Komoto I; Oka H; Kuwata K; Takeuchi M; Nakagawa F; Yoshisue K; Chiba M Cancer Chemother Pharmacol; 2015 Aug; 76(2):325-33. PubMed ID: 26084259 [TBL] [Abstract][Full Text] [Related]
22. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. Mulet N; Matos I; Noguerido A; Martini G; Élez ME; Argilés G; Tabernero J Expert Opin Pharmacother; 2018 Apr; 19(6):623-629. PubMed ID: 29537896 [TBL] [Abstract][Full Text] [Related]
23. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453 [TBL] [Abstract][Full Text] [Related]
24. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892 [TBL] [Abstract][Full Text] [Related]
25. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554 [TBL] [Abstract][Full Text] [Related]
26. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157 [TBL] [Abstract][Full Text] [Related]
27. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903 [TBL] [Abstract][Full Text] [Related]
28. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A; Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618 [TBL] [Abstract][Full Text] [Related]
29. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563 [TBL] [Abstract][Full Text] [Related]
30. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Doi T; Yoshino T; Fuse N; Boku N; Yamazaki K; Koizumi W; Shimada K; Takinishi Y; Ohtsu A Invest New Drugs; 2015 Oct; 33(5):1068-77. PubMed ID: 26163340 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts. Nukatsuka M; Nakagawa F; Takechi T Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349 [TBL] [Abstract][Full Text] [Related]
33. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
34. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment. Ottaiano A; Santorsola M; Ianniello M; Ceccarelli A; Casillo M; Sabbatino F; Petrillo N; Cascella M; Caraglia F; Picone C; Perri F; Sirica R; Zappavigna S; Nasti G; Savarese G; Caraglia M J Transl Med; 2024 Apr; 22(1):379. PubMed ID: 38650006 [TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435 [TBL] [Abstract][Full Text] [Related]
36. TAS-102 for the treatment of metastatic colorectal cancer. Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414 [TBL] [Abstract][Full Text] [Related]
38. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018 [TBL] [Abstract][Full Text] [Related]
40. Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. Kimura M; Go M; Iwai M; Ito D; Asano H; Usami E; Teramachi H; Yoshimura T Pharmazie; 2016 Apr; 71(4):218-21. PubMed ID: 27209703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]